Search Results
Your search for all items matches 35156 pages
Showing 30801 - 30850‘Frailty Profile’ Predicts Survival and Toxicities in Elderly Patients With Multiple Myeloma
A frailty score predicts mortality and the risk of toxicity in elderly patients with multiple myeloma and can be used to determine more suitable therapies for these patients, the International Myeloma Working Group reported in Blood. “Chronologic age, performance status, and physician’s clinical...
Chemotherapy Trial Results Overestimate Survival for Elderly Medicare Patients With Lung and Pancreatic Cancers
Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Elizabeth B. Lamont, MD, MS, of...
2015 Oncology Meetings
MAY 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)May 11-13 • Mainz, Germany For more information: www.meeting.cimt.eu 54th Annual Conference of the Particle Therapy Co-Operative GroupMay 18-23 • San Diego, California For more information: http://ptcog54.org American...
Clinical Trials Actively Recruiting Patients With Neuroblastoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or relapsed or refractory neuroblastoma. The studies include pilot, observational, phase I, phase II, and phase III trials investigating single-agent and...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Cancer Has Left an Indelible Mark on Me
Even though today I’m cancer-free, the experience of getting a cancer diagnosis and going through treatment leaves an indelible mark on your psyche—as well as your body—that time doesn’t erase. Once you have cancer, you become a cancer survivor, and that status doesn’t change. I’ve known many...
Robert Coleman, MD, Begins SGO and Foundation Presidency
Robert L. Coleman, MD, Professor, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, started his 1-year term as the 47th President of the Society of Gynecologic Oncology (SGO) and 5th President of the Foundation for Gynecologic...
FDA Approves Ramucirumab for Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with FOLFIRI (leucovorin, fluorouracil, irinotecan) for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab (Avastin)-,...
Bombarded With Changes in Health Care and Beyond, Gynecologic Oncologists Prepare for the Challenges Ahead
Physicians are being “bombarded” with changes in health care and beyond, Richard R. Barakat, MD, FACS, noted in his Presidential Address at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. These changes are being precipitated by steeply rising health-care costs amid...
A Cautionary Note on Psilocybin Therapy
The controversial nature of [psilocybin] is garnering attention before [the NYU investigators’] work has been peer-reviewed, which is concerning. Could psilocybin therapy be a helpful anxiolytic in any patient? Yes, I suppose, but I’d like to see the data. Is psilocybin an anxiolytic in cancer...
Researchers Discuss Pilot Study on Hallucinogenic Therapies for Cancer Anxiety
Although varying levels of existential distress are near-ubiquitous among patients with cancer, evidence-based interventions in this clinical area remain somewhat elusive. Seeking to explore novel approaches in the palliative care environment, New York University (NYU) School of Medicine principal...
Childhood Cancers: Significant Medical Success but Many Psychosocial Needs Still Unmet
Treatment of childhood cancer is remarkably successful, but still, 2,000 children die of it each year, and for some forms of the disease, no progress has been made at all, said Otis Brawley, MD, Chief Medical Officer, American Cancer Society (ACS). “At least half of all pediatric cancer survivors...
Conquer Cancer Foundation
Be on the lookout for a big announcement from the Conquer Cancer Foundation at the 2015 Annual Meeting. How will you be able to take part? By making a gift in support of vital cancer research, education, and tools to improve the quality of cancer care. Donations can be made online at ccf.asco.org,...
Maintenance of Certification Activities: Earn Points at the ASCO Annual Meeting
The 2015 ASCO Annual Meeting will feature three activities to help attendees earn American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points while onsite. Annual Meeting Practice-Centered Session MOC Self-Assessment Activity This activity is designed for attendees who want ...
Providing Survivorship Care Bundle: Oncology Provider Guides and Patient Guides
ASCO’s new product bundle combines provider and patient information about cancer survivorship. Providing High Quality Survivorship Care in Practice: An ASCO Guide aims to assist oncologists and other clinicians with implementing high-quality survivorship care programs within their practice. The...
Five Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO15 on Twitter to follow and participate in the conversation around the Annual Meeting in real time! During last year’s Annual Meeting, over 43,000 Tweets were sent by more than 8,500 individuals, reaching an estimated 145 million Twitter users. Tweets about the...
Save the Date: Community Research Forum 2015 Annual Meeting
The Community Research Forum (CRF) will hold its Annual Meeting this fall, September 20 to 21, 2015. This meeting will provide an exclusive opportunity for community-based researchers and research staff to network and collaborate with colleagues from all types of research sites and programs. It...
ASCO Submits Comments to FDA on Next-Generation Sequencing Tests
ASCO submitted comments to the U.S. Food and Drug Administration (FDA) on its white paper, “Optimizing FDA’s Regulatory Oversight of Next-Generation Sequencing Diagnostic Tests.” The Society expressed its support of the exploration of new regulatory strategies for next-generation sequencing...
Enhance Your Annual Meeting Experience With Attendee Resources
At the end of May, more than 25,000 oncology professionals from around the world will meet in Chicago for the 2015 ASCO Annual Meeting. This year’s theme, “Illumination & Innovation: Transforming Data into Learning,” reflects the current state of oncology. The accelerating volume and variety of ...
USP Urged to Work With ASCO on Hazardous Drug Regulations
In July 2014, ASCO President Peter Paul Yu, MD, FACP, FASCO, wrote a lengthy letter to the CEO of the U.S. Pharmacopeial Convention (USP), commenting on the proposal for Chapter <800> regulations, saying “it is not evidence-based and is fundamentally flawed” and urging USP to “engage with...
Maryland Oncologists Faced With Navigating the Maze of Chemotherapy Safety Regulations
In March 2013, 60 Minutes aired a devastating piece about a Massachusetts compounding center that shipped an injectable steroid contaminated with fungus. One of the many ripple effects from this story of horrendous patient suffering was felt in Maryland, where it sparked legislative action in the...
Informing Decision-Making About Mammography Screening
Overdiagnosis associated with breast cancer screening has been the subject of much attention in recent years. The notion that cancer screening—largely believed to be beneficial—could actually be harmful is simultaneously fascinating and difficult to believe. With the publication of multiple studies ...
Impact of Informed Decision-Making on Breast Cancer Screening
In a study reported in Lancet, Jolyn Hersch, MApplSc, of the University of Sydney, and colleagues found that use of a decision aid containing information on overdetection in breast cancer screening was associated with an increased rate of informed choice regarding screening, a reduced rate of...
Brentuximab Vedotin After Autologous Stem Cell Transplantation in High-Risk Hodgkin Lymphoma: Implications of the AETHERA Trial
Hodgkin lymphoma is generally thought to be a malignancy with a favorable prognosis. Overall, approximately 80% of patients will have durable, long-term remissions with initial chemotherapy. Some patients, however, demonstrate evidence of disease progression, and these patients usually receive...
Improved Progression-Free Survival With Brentuximab Vedotin After Transplantation in Hodgkin Lymphoma Patients
In the phase III AETHERA trial reported in The Lancet, Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that brentuximab vedotin (Adcetris) consolidation therapy after autologous stem cell transplantation prolonged progression-free survival by 18 months vs...
Combining Antiangiogenic and Vascular-Disrupting Agents Improves Progression-Free Survival in Persistent Ovarian Cancer
“Bevacizumab [Avastin] prevents new blood vessels from growing, but what about the blood vessels that are already in the tumor?” Presenting that challenge to participants at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Chicago, Bradley J. Monk, MD, of the University of...
Groups Join Together to Form Ovarian Cancer Research Team
Stand Up To Cancer , Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research (AACR), announced the formation of a “Dream Team” devoted to ovarian cancer research at the AACR Annual Meeting 2015....
Immunosignature Technology May Detect Ovarian Cancer With a Drop of Blood
“Immunosignatures” may be well suited to enable the detection of ovarian cancer, researchers reported at the National Comprehensive Cancer Network (NCCN) 20th Annual Conference.1 “We developed a new concept for disease detection based on immunosignatures. From a drop of blood, HealthTell’s...
NCCN Foundation Awards Grants to Six Young Investigators
The National Comprehensive Cancer Network (NCCN) Foundation has awarded grants to six young investigators from NCCN Member Institutions. These awardees, dedicated to advancing and discovering new treatments for cancer, enhancing quality, and improving patient education, represent the fifth series...
NCCN Posters of Interest Included Studies in Kidney, Breast, and Endometrial Cancers, Melanoma, and Cost Issues
The quality and quantity of original research presented at the National Comprehensive Cancer Network (NCCN) Annual Conference continue to grow since poster sessions debuted a few years ago. The ASCO Post offers summaries for just a few that caught our eye, out of more than 65 presented this year....
Expert Point of View: Louis Weiner, MD
In the past 10 years, we have begun to unlock the keys to the puzzle of the body’s immune system. The study presented here drives home the important point that we can elicit immune responses with unusual durability,” said Louis Weiner, MD, Director of the Georgetown Lombardi Cancer Center in...
Combination Immunotherapy Better Than Monotherapy in Advanced Melanoma
As clinical research struggles to keep up with the pace of new immunotherapies, one of the burning questions is how best to combine the new drugs. A new study found that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is superior to ipilimumab alone as front-line therapy for untreated ...
Crizotinib Receives Breakthrough Therapy Designation for ROS1-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to crizotinib (Xalkori) for the potential treatment of patients with ROS1-positive non–small cell lung cancer (NSCLC). Crizotinib currently is FDA-approved for the treatment of patients with metastatic NSCLC...
José Baselga, MD, PhD, Inaugurated as AACR President
The American Association for Cancer Research (AACR) inaugurated José Baselga, MD, PhD, as President for 2015–2016 at the AACR Annual Meeting 2015. Dr. Baselga, an internationally recognized physician-scientist whose research focuses on the clinical development of novel molecularly targeted agents...
After Decades of Uncertainty, the Sustainable Growth Rate Formula Is Repealed by Congress
The U.S. Congress recently did something remarkable: both parties reached across the aisle and overwhelmingly passed H.R. 2, a bill that will permanently repeal the sustainable growth rate (SGR), the problematic formula for Medicare reimbursement. It just needed the President’s signature, which it...
Experts Debate: Can We Cure Metastatic Breast Cancer?
Can metastatic breast cancer ever be cured? This issue was debated at the 32nd Annual Miami Breast Cancer Conference by two experts in the field: George W. Sledge, Jr, MD, Professor of Medicine at Stanford University Medical Center, Palo Alto, California, and Clifford A. Hudis, MD, Chief of the...
ASCO Releases 2015 Report on The State of Cancer Care in America
In March, ASCO published its second annual report, The State of Cancer Care in America: 2015.1 Its findings show a mixed landscape, on the one hand, spotlighting advances in therapy and improving survival rates, but on the other, describing a cancer care system under stress from increasing demand...
Creating a Collective Path Forward to Optimize Value in Cancer Care
The Centers for Medicare and Medicaid Services projects that U.S. health-care spending will reach $4.3 trillion and account for 19.3% of the nation’s gross domestic product by 2019.1 Although cancer care represents a small fraction of overall health-care costs, the cost of cancer care is rapidly...
Expert Point of View: Suzanne L. Topalian, MD
Press conference moderator Suzanne L. Topalian, MD, Director of the Melanoma Program at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, said, “The approval of ipilimumab [Yervoy] as first-line therapy for advanced melanoma in 2011 was a landmark moment. This was the ...
Practice-Changing Study: Pembrolizumab Outperforms Ipilimumab in Advanced Melanoma
Pembrolizumab (Keytruda) proved superior to ipilimumab (Yervoy) for the treatment of unresectable advanced melanoma in the global phase III KEYNOTE-006 trial. Pembrolizumab significantly improved overall survival, progression-free survival, and overall response rate compared with ipilimumab, which...
Profile: Julie M. Vose, MD, MBA, FASCO, Making a Difference in Both Clinical Medicine and Research
At this year’s ASCO Annual Meeting, Julie M. Vose, MD, MBA, FASCO, will begin her term as the Society’s 51st President. It is fitting that the meeting will be held in Chicago, the city where the first seven visionaries met over lunch in 1964 to formulate a medical organization centered on cancer...
HOPA Announces New President and 2015 Membership Award Winners
The Hematology/Oncology Pharmacy Association (HOPA) has elected Scott Soefje, PharmD, MBA, BCOP, FCCP, to serve as President for the 2015–2016 term. His term began at the 11th HOPA Annual Conference, held March 25–28. Dr. Soefje has served as President-Elect since March 2014. Dr. Soefje is a...
p53 Takes Center Stage
BOOKMARKTitle: p53: The Gene That Cracked the Cancer CodeAuthor: Sue ArmstrongPublisher: Bloomsbury PublishingPublication date: November 20, 2014Price: $19.98; hardcover, 288 pages Completed in April 2003, the Human Genome Project was one of the greatest feats of scientific exploration, an inward ...
Nicholas J. Petrelli, MD, Receives Service Award
Nicholas J. Petrelli, MD, Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System, received the 2015 Service Award from the Delaware Bio Science Association. Delaware Bio Science is a trade association focused solely on ...
Cancer Survivors: Facts and Figures
The National Cancer Institute’s Office of Cancer Survivorship recently issued the following data: As of January 2014, it is estimated that there are 14.5 million cancer survivors in the United States. This represents over 4% of the population, according to a report published recently.1 The...
People Living With HIV in the United States Have a 50% Excess Cancer Risk
The nearly 900,000 people in the United States living with diagnosed human immunodeficiency virus (HIV) infection have an excess cancer risk of 50%, according to a joint analysis of data by the National Cancer Institute and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention,...
Therapy for Hepatitis C Virus Infection in Patients With Cancer May Prevent Liver Disease Progression
“Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer,” Harrys A. Torres, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston noted in the Journal of the National Comprehensive Cancer Network. To rectify that situation, the researchers...
EGFR L858R Mutation in Blood Sample May Serve as Surrogate for Biopsy in Determining EGFR-Mutation Status
Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown that the EGFR L858R...
Prior Cancer Does Not Affect Outcomes Among Patients With Advanced Lung Cancer, Suggesting They Be Included in Clinical Trials
Analysis of data from 102,929 patients with stage IV lung cancer found that “prior cancer does not convey an adverse effect on clinical outcomes, regardless of prior cancer stage, type, or timing.” Based on these findings, investigators from the Harold C. Simmons Cancer Center, University of Texas...
Emergency Room Visits and Hospitalizations Are Common Among Women With Early Breast Cancer Receiving Chemotherapy
Emergency room visits and hospitalizations are common among patients with early breast cancer receiving chemotherapy, particularly among those receiving a regimen containing docetaxel, according to a study supported by the Ontario Institute of Cancer Research, Toronto. “In this population-based...
